Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
Assessment of statistical significance and clinical relevance.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
New approaches in the management of multiple sclerosis.
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
FTY720 in patients with primary progressive multiple sclerosis (INFORMS)
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Predictive value of early brain atrophy on response in patients treated with interferon β.

Pages